Home › US companies › Glaukos

Glaukos

GKOS · NYSE · Surgical & Medical Instruments & Apparatus
Insider buys (12 months)
0
Insider sales (12 months)
$69.3M
8-K reports (12 months)
10
Tracked investors holding
2

At a glance

Glaukos reported 2025 revenue of $507.4M, up 32.3% from $383.5M in 2024. Over 4 years since 2021 ($294M), that is growth of about 14.6% a year. Operating margin was -39.3%, down from -11.2% in 2021. 2025 was the highest revenue year in this period. The company posted a loss in 2021, 2022, 2023, 2024 and 2025.

In the last 12 months 8 insiders reported 0 open-market purchases and 31 sales ($69.3M). 19 of the sales were made under pre-arranged 10b5-1 plans. The largest was a sale of $31.6M by CHAIRMAN & CEO Thomas William Burns on Jan 20, 2026.

Glaukos filed 10 current reports (Form 8-K) in the last 12 months, most often for results of operations (5), regulation fd disclosure (4) and shareholder vote results (1).

2 of the 20 investors tracked here held Glaukos at the last quarter end, worth $21M combined. It is the largest weight for Renaissance Technologies (0% of its portfolio), followed by Bridgewater Associates (0%). New this quarter: Bridgewater Associates. Added: Renaissance Technologies.

Annual results

2021
Revenue $294M
Op. -$32.9M
2022
Revenue $282.9M
Op. -$82.3M
2023
Revenue $314.7M
Op. -$128.7M
2024
Revenue $383.5M
Op. -$122.4M
2025
Revenue $507.4M
Op. -$199.6M
RevenueOperating income (or net income)SEC XBRL annual filings, fiscal years mapped to calendar years
Year20212022202320242025
Net income-$49.6M-$99.2M-$134.7M-$146.4M-$187.7M
Diluted EPS$-1.07$-2.09$-2.78$-2.77$-3.28

Fiscal year ends Dec 31 · incorporated in DE

Tracked investors holding (13F)

Renaissance TechnologiesAdded$20.6M · 0.0% · held 5 quarters
Bridgewater AssociatesNew$463K · 0.0% · held 4 quarters

Weight is the share of each investor's portfolio, as of the quarter end.

Current reports (8-K, last 12 months)

Insider open-market trades (last 12 months)

Source: SEC EDGAR. How figures are combined